Isavuconazonium sulfate for the treatment of fungal infection

R. C. Walker, J. D. Zeuli, Zelalem Temesgen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalDrugs of Today
Volume52
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Mucormycosis
Azoles
Aspergillosis
Mycoses
Fungi
Prodrugs
Drug Interactions
Yeasts
Safety
Therapeutics
Pharmaceutical Preparations
Invasive Fungal Infections
isavuconazole
Voriconazole
Clinical Studies

Keywords

  • Antifungal
  • BAL-8557
  • Isavuconazole
  • Isavuconazonium sulfate
  • Triazole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Isavuconazonium sulfate for the treatment of fungal infection. / Walker, R. C.; Zeuli, J. D.; Temesgen, Zelalem.

In: Drugs of Today, Vol. 52, No. 1, 01.01.2016, p. 7-16.

Research output: Contribution to journalArticle

Walker, R. C. ; Zeuli, J. D. ; Temesgen, Zelalem. / Isavuconazonium sulfate for the treatment of fungal infection. In: Drugs of Today. 2016 ; Vol. 52, No. 1. pp. 7-16.
@article{afe76bced8e24b2bb6223d5082ca4cf2,
title = "Isavuconazonium sulfate for the treatment of fungal infection",
abstract = "Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.",
keywords = "Antifungal, BAL-8557, Isavuconazole, Isavuconazonium sulfate, Triazole",
author = "Walker, {R. C.} and Zeuli, {J. D.} and Zelalem Temesgen",
year = "2016",
month = "1",
day = "1",
doi = "10.1358/dot.2016.52.1.2404002",
language = "English (US)",
volume = "52",
pages = "7--16",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Isavuconazonium sulfate for the treatment of fungal infection

AU - Walker, R. C.

AU - Zeuli, J. D.

AU - Temesgen, Zelalem

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.

AB - Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.

KW - Antifungal

KW - BAL-8557

KW - Isavuconazole

KW - Isavuconazonium sulfate

KW - Triazole

UR - http://www.scopus.com/inward/record.url?scp=84960487719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960487719&partnerID=8YFLogxK

U2 - 10.1358/dot.2016.52.1.2404002

DO - 10.1358/dot.2016.52.1.2404002

M3 - Article

C2 - 26937491

AN - SCOPUS:84960487719

VL - 52

SP - 7

EP - 16

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 1

ER -